Dr. Anis is a Professor in the School of Population and Public Health (SPPH) at the University of British Columbia (UBC), a respected health economist and sought-after speaker on the topic of economic evaluation and resource allocation for health care interventions. His primary areas of expertise include Canadian competition policy in the pharmaceutical industry and the cost-effectiveness of treatments for HIV/AIDS and rheumatoid arthritis. Dr. Anis is the Director of the Centre for Health Evaluation and Outcomes Sciences (CHÉOS), one of the largest and most productive multidisciplinary health outcomes research groups in Canada. He is also the National Director of the CIHR Canadian HIV Trials Network (CTN), a Senior Scientist at the Arthritis Research Centre of Canada, and a Fellow of the Canadian Academy of Health Sciences. Between 2008 and 2013 Dr. Anis was the Co-Lead of the Health Services and Systems theme at SPPH.
Dr. Anis’s research activities have been extensive. His earliest research into the pharmaceutical industry demonstrated that pricing regulations as they were being implemented by provincial drug plans were responsible for higher generic drug prices in Canada. As the founding director of the Pharmacoeconomic Initiative of BC, Dr. Anis developed a framework under which pharmaceutical firms seeking to list drugs on the provincial formulary were required to submit cost-effectiveness data to inform the government’s decision. In the 1990s, Dr. Anis was among the first scholars worldwide to demonstrate the cost-effectiveness of anti-retroviral therapy (ART) and his work helped shape economic policies governing access to this critical treatment for persons living with HIV/AIDS. As an expert in cost-effectiveness analysis, Dr. Anis has also made important contributions to arthritis research. In the area of rheumatoid arthritis, Dr. Anis has been involved in several influential studies of biologic therapies, which have informed reimbursement policies surrounding these treatments in Canada and the UK.
For the past 19 years, Dr. Anis has played an integral role in educating students in health economics and related disciplines. He was responsible for the design of a novel curriculum and delivery format for the Master of Health Administration program at UBC, comprised of 1.5 credit modules taught during weekends in partnership with the Sauder School of Business. This program has become one of the most successful new programs at UBC, training future health care administrators while they maintain relevant employment in the field. Dr. Anis was also responsible for the establishment of an MD/MHA program, currently being piloted with 2 MD students. As a Professor, Dr. Anis is committed to positive and fruitful working relationships with trainees, and has supervised 25 Master’s and 16 PhD students over the last 21 years. The success of his trainees and staff is a top priority for Dr. Anis and he values the energy and dedication of his wide network of colleagues and students.
Current Ph.D. Students:
Stephanie Harvard (SPPH)
Shan (Alex) Jiang (SPPH)
Jamie Forrest (SPPH)
Mohammad Atiquzzaman (Faculty of Pharmaceutical Sciences)
Anis AH, Zhang W, Bansback N, Guh DP, Amarsi Z, Birmingham CL. Obesity and overweight in Canada: An updated cost-of-illness study. Obesity Reviews. (Epub ahead of print, PMID: 19413707)
Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, Sato R. The Effect of Etanercept on Work Productivity in Patients with Early Active Rheumatoid Arthritis: Results from the COMET Study. Rheumatology. 2009;48(10):1283-9
Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Annals of Internal Medicine. 2009;3:151(9):612-21
Nosyk B, MacNab Y, Sun H, Fischer B, Marsh D, Schechter M, Anis A. Proportional hazards frailty models for recurrent methadone maintenance treatment. American Journal of Epidemiology. 2009;170(6):783-92
Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. A Randomized Trial of Diacetylmorphine vs. Methadone for Opioid Addiction. New England Journal of Medicine. 2009;361(8):777-86
Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, Clarke AE, Gignac MA, Anis A. Not all “quality-adjusted life years” are equal. Journal of Clinical Epidemiology. 2007;60(6):616-624
Anis AH, Guh DP, Woolcott J. Lowering generic drug prices: less regulation equals more competition. Medical Care, 2003;41(1):135-41
Anis AH, Guh D, Wang X. A Dog’s Breakfast: Prescription Drug Coverage Varies Widely Across Canada. Medical Care, 2001;39(4):315-326
Anis AH, LD Lynd, Wang X, King G, Spinelli JJ, Fitzgerald M, Bai T, Pare P. Double trouble: Excessive ß-agonist use linked to increased use of health care resources. Canadian Medical Association Journal, 2001;164(5):625-631
Anis AH, and Wen Quan. Price regulation of pharmaceutical in Canada. Journal of Health Economics, 1998;17(1):21-38
Anis AH. Pharmaceutical prices with insurance coverage and formularies. Canadian Journal of Economics, 1992;25(2):420-437
Some non-health-economic outliers:
Anis AH, Benarroch M, Wen Q. Persistent Protection in an international exit game. Journal of International Economics, 2002;56:465-487
Anis AH & Ross TW. Imperfect competition and pareto-improving strategic trade policy. Journal of International Economics, 1992;33:363-371